| # | Title | Journal | Year | Citations |
|---|
| 1 | Molecular pathways in non-alcoholic fatty liver disease | Clinical and Experimental Gastroenterology | 2014 | 279 |
| 2 | Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease | Clinical and Experimental Gastroenterology | 2014 | 226 |
| 3 | Lactose intolerance: diagnosis, genetic, and clinical factors | Clinical and Experimental Gastroenterology | 2012 | 164 |
| 4 | Fecal calprotectin in inflammatory bowel disease | Clinical and Experimental Gastroenterology | 2016 | 134 |
| 5 | Postoperative pancreatic fistula: a review of traditional and emerging concepts | Clinical and Experimental Gastroenterology | 2018 | 130 |
| 6 | Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date | Clinical and Experimental Gastroenterology | 2016 | 115 |
| 7 | Enzyme replacement therapy for pancreatic insufficiency: present and future | Clinical and Experimental Gastroenterology | 2011 | 114 |
| 8 | Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori | Clinical and Experimental Gastroenterology | 2012 | 114 |
| 9 | Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis | Clinical and Experimental Gastroenterology | 2008 | 107 |
| 10 | <p>Exocrine pancreatic insufficiency: prevalence, diagnosis, and management</p> | Clinical and Experimental Gastroenterology | 2019 | 105 |
| 11 | Interleukins in chronic liver disease: lessons learned from experimental mouse models | Clinical and Experimental Gastroenterology | 2014 | 99 |
| 12 | Protein losing enteropathy: comprehensive review of the mechanistic association with clinical and subclinical disease states | Clinical and Experimental Gastroenterology | 2017 | 97 |
| 13 | Autoimmune atrophic gastritis: current perspectives | Clinical and Experimental Gastroenterology | 2017 | 96 |
| 14 | Acute gastroenteritis: from guidelines to real life | Clinical and Experimental Gastroenterology | 2010 | 95 |
| 15 | Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review | Clinical and Experimental Gastroenterology | 2015 | 89 |
| 16 | Bouveret syndrome: current management strategies | Clinical and Experimental Gastroenterology | 2018 | 82 |
| 17 | Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach | Clinical and Experimental Gastroenterology | 2015 | 81 |
| 18 | <p>Eosinophilic gastroenteritis: diagnosis and clinical perspectives</p> | Clinical and Experimental Gastroenterology | 2019 | 80 |
| 19 | Inflammatory bowel disease and anxiety: links, risks, and challenges faced | Clinical and Experimental Gastroenterology | 2015 | 76 |
| 20 | A systematic review of disease-related stigmatization in patients living with inflammatory bowel disease | Clinical and Experimental Gastroenterology | 2016 | 71 |
| 21 | The impact of biologics on health-related quality of life in patients with inflammatory bowel disease | Clinical and Experimental Gastroenterology | 2009 | 68 |
| 22 | Hereditary pancreatitis: current perspectives | Clinical and Experimental Gastroenterology | 2016 | 67 |
| 23 | <p>Iatrogenic bile duct injury: impact and management challenges</p> | Clinical and Experimental Gastroenterology | 2019 | 67 |
| 24 | A systematic review of transarterial embolization versus emergency surgery in treatment of major nonvariceal upper gastrointestinal bleeding | Clinical and Experimental Gastroenterology | 2014 | 66 |
| 25 | Reduced expression of aquaporins in human intestinal mucosa in early stage inflammatory bowel disease | Clinical and Experimental Gastroenterology | 2015 | 62 |
| 26 | Self-management in patients with inflammatory bowel disease: strategies, outcomes, and integration into clinical care | Clinical and Experimental Gastroenterology | 2016 | 61 |
| 27 | Measuring disease activity in Crohn's disease: what is currently available to the clinician | Clinical and Experimental Gastroenterology | 2014 | 60 |
| 28 | Influence of <em>Saccharomyces boulardii</em> CNCM I-745 on the gut-associated immune system | Clinical and Experimental Gastroenterology | 2016 | 60 |
| 29 | DCLK1 immunoreactivity in colorectal neoplasia | Clinical and Experimental Gastroenterology | 2012 | 59 |
| 30 | Diagnosis and management of microscopic colitis: current perspectives | Clinical and Experimental Gastroenterology | 2014 | 59 |
| 31 | Rikkunshito, a traditional Japanese medicine, suppresses cisplatin-induced anorexia in humans | Clinical and Experimental Gastroenterology | 2011 | 58 |
| 32 | A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis | Clinical and Experimental Gastroenterology | 2019 | 58 |
| 33 | <p>Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease – associations with disease phenotype, treatment, and outcome</p> | Clinical and Experimental Gastroenterology | 2019 | 58 |
| 34 | Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions | Clinical and Experimental Gastroenterology | 2018 | 53 |
| 35 | <p>Why targeting the microbiome is not so successful: can randomness overcome the adaptation that occurs following gut manipulation?</p> | Clinical and Experimental Gastroenterology | 2019 | 53 |
| 36 | Essential phospholipids in fatty liver: a scientific update | Clinical and Experimental Gastroenterology | 2016 | 52 |
| 37 | Iron deficiency anemia in patients with inflammatory bowel disease | Clinical and Experimental Gastroenterology | 2013 | 51 |
| 38 | <p>Benign biliary strictures: prevalence, impact, and management strategies</p> | Clinical and Experimental Gastroenterology | 2019 | 51 |
| 39 | US perspective on gluten-related diseases | Clinical and Experimental Gastroenterology | 2014 | 50 |
| 40 | Secondary sclerosing cholangitis in critically ill patients: current perspectives | Clinical and Experimental Gastroenterology | 2017 | 49 |
| 41 | Liver function tests in identifying patients with liver disease | Clinical and Experimental Gastroenterology | 2018 | 49 |
| 42 | Exercise in patients with inflammatory bowel diseases: current perspectives | Clinical and Experimental Gastroenterology | 2018 | 48 |
| 43 | Advances, problems, and complications of polypectomy | Clinical and Experimental Gastroenterology | 2014 | 47 |
| 44 | CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease | Clinical and Experimental Gastroenterology | 2015 | 47 |
| 45 | Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome | Clinical and Experimental Gastroenterology | 2016 | 47 |
| 46 | <p>Beneficial effects of <em>Saccharomyces boulardii</em> CNCM I-745 on clinical disorders associated with intestinal barrier disruption</p> | Clinical and Experimental Gastroenterology | 2019 | 47 |
| 47 | Epidemiology of viral hepatitis in Sudan | Clinical and Experimental Gastroenterology | 2008 | 46 |
| 48 | Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease | Clinical and Experimental Gastroenterology | 2014 | 46 |
| 49 | A model of blood-ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in the multiple organs involved in the production, catabolism, and excretion of ammonia in humans | Clinical and Experimental Gastroenterology | 2018 | 46 |
| 50 | <p>Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines</p> | Clinical and Experimental Gastroenterology | 2019 | 44 |
